NASDAQ: TRAWTraws Pharma Inc Stock
$2.33-0.14 (-5.67%)
Updated Dec 11, 2025
TRAW Price
$2.33
Fair Value Price
N/A
Market Cap
$18.62M
52 Week Low
$0.97
52 Week High
$19.44
P/E
0.02x
P/B
4.1x
P/S
5.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.85M
Earnings
$93.35M
Gross Margin
100%
Operating Margin
3,280.04%
Profit Margin
3,280%
Debt to Equity
1.74
Operating Cash Flow
-$19M
Beta
1.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TRAW Overview
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TRAW's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TRAW
Ranked#430 of 489
Ranked#430 of 489
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $320.84 | A | |
| $20.62 | A | |
| $7.16 | A |
Be the first to know about important TRAW news, forecast changes, insider trades & much more!
TRAW News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRAW scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRAW was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TRAW is good value based on its earnings relative to its share price (0.02x), compared to the US market average (45.84x)
P/E vs Market Valuation
TRAW is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more TRAW due diligence checks available for Premium users.
Valuation
TRAW price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.02x
Industry
159.38x
Market
45.84x
TRAW is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TRAW is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
TRAW price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.1x
Industry
5.34x
TRAW is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRAW's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.0M
Profit Margin
0%
TRAW's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TRAW's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.4M
Liabilities
$7.9M
Debt to equity
1.74
TRAW's short-term assets ($9.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRAW's short-term assets ($9.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRAW's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TRAW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.0M
Investing
-$2.6M
Financing
-$62.0k
TRAW's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRAW vs Biotech Stocks
Traws Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.